|
|
|
 |
|
|
| News & Views |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Top Stories |
|
|
|
|
|
|
|
|
|
|
| Finance Tools |
|
|
|
|
|
|
|
|
|
|
|
| Search |
|
|
|
|
|
|
About Us
|
|
|
|
|
|
|
|
|
| Other Digital Look Sites |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 52 wk Low/High | 1969/ 2572 |
|
|
|
| All prices are delayed by 15 mins |
|
| Price Data |
|
|
| Change Over |
|
Chg |
%Chg |
| 1 week | | 19 | +0.78 |
| 1 month | | -127 | -4.98 |
| 1 year | | 441 | +22.18 |
|
|
|
|
|
|
|
|
|
| Company News | Related Market News |
|
-
Wed 19 Jun 2013
FTSE 100-listed telecommunications giant BT has reported that Gavin Patterson will succeed Ian Livingston as Chief Executive Officer (CEO) of BT Group.
-
Wed 19 Jun 2013
Peel Hunt has kept its 'buy' rating and 630p target price for chip designer Imagination Technologies following the group's annual results on Wednesday, saying that shares are undervalued.
-
Wed 19 Jun 2013
Aggreko: UBS cuts target price from 1975p to 1850p downgrading from buy to neutral. JP Morgan revises target price from 1870p to 1800p and retains a neutral rating.
-
Wed 19 Jun 2013
Processor technology group Imagination Technologies on Wednesday revealed a decline in annual profits due to a sharp increase in operating expenses (opex), though management sounded a confident note saying that a number of substantial investments have built a 'strong platform for growth'.
-
Wed 19 Jun 2013
Processor technology group Imagination Technologies saw annual revenues grow by a fifth after a better-than-expected increase in unit shipments, though profits more than halved after a jump in opex and continuing struggles at its loss-making digital radio division, Pure.
-
Wed 19 Jun 2013
Micro Focus International reported a rise in annual pre-tax profits as the software products group kept a tight rein on costs.
-
Wed 19 Jun 2013
AstraZeneca has completed the fourth phase of its clinical trial of diabetes treatment Onglyza.
-
Tue 18 Jun 2013
Pharmaceutical company AstraZeneca is launching its global headquarters at the Cambridge Biomedical Campus.
-
Tue 18 Jun 2013
FTSE 100-listed global pharmaceuticals company GlaxoSmithKline(GSK) has received an offer for its thrombosis brands and Notre-Dame de Bondeville (NDB) site from Aspen Global Incorporated and Aspen Pharmacare.
-
Tue 18 Jun 2013
Investec has maintained its 'buy' stance for SDL despite a severe profit warning from the translation and communications software firm on Tuesday, saying that it expects the company's performance to improve next year.
-
Tue 18 Jun 2013
Alternative Networks: Westhouse Securities upgrades from neutral to add with a target price of 350p.
-
Tue 18 Jun 2013
Shares of translation and communications software firm SDL plummeted after the group lowered its outlook for the current financial year following a weaker than expected first half performance.
-
Mon 17 Jun 2013
Antofagasta: UBS reduces target price from 1140p to 1050p, while upgrading from neutral to buy.
-
Mon 17 Jun 2013
Imagination Technologies has signed a licence agreement with Cavium to provide its latest MIPSr5 architecture.
-
Fri 14 Jun 2013
British Sky Broadcasting has landed a counter-punch on rival BT as both companies duke it out for sports fans and broadband customers.
-
Thu 13 Jun 2013
African Barrick Gold: Citi moves target price from 175p to 124p and maintains a sell recommendation.
-
Wed 12 Jun 2013
Credit Suisse has raised its target price for telecommunications giant BT Group from 300p to 350p and maintained its 'outperform' rating on the stock.
-
Wed 12 Jun 2013
Mobile telecommunications giant Vodafone Grouphas confirmed a preliminary approach to German cable operator Kabel Deutschland.
-
Wed 12 Jun 2013
FTSE 100-listed mobile communications company Vodafone has today announced the addition of two new high performance smartphones designed to accelerate the adoption of mobile internet usage within the mass market.
-
Wed 12 Jun 2013
Aberdeen Asset Management: Canaccord Genuity cuts target price from 460p to 440p, while leaving its buy recommendation unchanged.
|
| |
|
|
|
|
Snapshot 